Related Experiment Video
Updated: Sep 2, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Recombinant hepatitis B vaccine for prevention of hepatitis B infection
H H Gill1, H G Desai, V S Trikannad
1Department of Gastroenterology, BYL Nair Ch Hospital, Bombay.
Abstract:
Twenty-five resident doctors were given 1 ml (20 micrograms) of recombinant hepatitis B vaccine intramuscularly in the deltoid region at 0, 1 and 6 months. Seroconversion rates at 1, 2, 3, 7 and 8 months were 8%, 48%, 64%, 96% and 100% respectively. Acceptability of the vaccine was 100%. The recombinant hepatitis B vaccine is safe and efficacious, with seroconversion rates comparable to the plasma derived vaccine, and has negligible side effects.
Related Concept Videos
Viral Recombination
Cross-reactivity
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Hepatitis
Viral Hepatitis I: Introduction

